700874-72-2 | 4-[2-(6-Methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%	in stock	$13.00	$9.00
10mg	98%	in stock	$19.00	$14.00
25mg	98%	in stock	$31.00	$22.00

Description

• Catalog Number: AB44683
• Chemical Name: 4-[2-(6-Methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
• CAS Number: 700874-72-2
• Molecular Formula: C22H19N5O
• Molecular Weight: 369.4192
• MDL Number: MFCD12923319
• SMILES: Cc1cccc(n1)c1nn2c(c1c1ccnc3c1cc(cc3)C(=O)N)CCC2

Computed Properties

• Complexity: 585
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 3
• XLogP3: 2.4

Literature

• Prenatal nicotine exposure intergenerationally programs imperfect articular cartilage via histone deacetylation through maternal lineage.

  Toxicology and applied pharmacology 20180801

• Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model.

  Archives of toxicology 20180701

• Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.

  Oncotarget 20180123

• Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.

  Journal of medicinal chemistry 20140522

• Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.

  Journal of medicinal chemistry 20080410